A peptide-oligonucleotide linker may look correct on paper, yet still fail during synthesis, purification, conjugation, or biological testing if the attachment handle is placed at the wrong position. For custom peptide-oligonucleotide conjugates, the practical question is not only "which linker should be used?" but also "where should each reactive group be placed, what should be protected, and how will the final orientation affect function?" A successful specification must define the peptide sequence, oligonucleotide sequence, attachment site, functional group, spacer design, purification requirement, and intended assay context before chemistry begins.
This guide translates functional group and attachment site choices into a practical specification framework for researchers, peptide chemists, oligonucleotide vendors, procurement teams, and project managers preparing custom conjugation inquiries. It focuses on how to describe peptide-side and oligonucleotide-side handles clearly so that the final conjugate is chemically feasible, analytically verifiable, and suitable for the intended biological or analytical use.
Functional group placement controls the orientation, accessibility, and chemical selectivity of a peptide-oligonucleotide conjugate. The linker itself may provide the desired length, hydrophilicity, rigidity, or cleavability, but the final product still depends on where the reactive handle is introduced. A handle positioned too close to a binding motif may reduce affinity. A handle placed on a residue that also appears elsewhere in the peptide may cause mixed products. An oligonucleotide modified at the wrong terminus may reverse the intended orientation in a hybridization, delivery, or immobilization assay.
Site-specific conjugation uses a defined functional group at a defined molecular position. On the peptide side, this may be an N-terminal azide, C-terminal cysteine, side-chain lysine modification, or spacer-bearing handle. On the oligonucleotide side, this may be a 5' amine, 3' thiol, internal azide, alkyne-modified base, or other custom modification. The advantage is that the final conjugate can be described as a single intended structure rather than a distribution of positional isomers.
For quotation and feasibility review, site specificity should be expressed explicitly. Instead of stating "peptide with linker," a stronger specification would state "peptide sequence with N-terminal azidoacetic acid and Ahx spacer for conjugation to 5' alkyne-modified DNA." This gives the synthesis and conjugation team enough information to evaluate chemistry, competing functional groups, expected purification difficulty, and analytical confirmation.
Random modification often occurs when a reactive chemistry is chosen without considering all reactive sites present in the peptide or oligonucleotide. For example, an amine-reactive chemistry may modify the N-terminus and lysine side chains unless the design controls which amine should react. A thiol-reactive chemistry may work well with a single engineered cysteine but becomes ambiguous if the peptide contains multiple free cysteines or disulfide-forming motifs. Random modification creates product heterogeneity, complicates LC-MS interpretation, reduces yield of the desired conjugate, and may produce batches with different biological performance.
Avoiding random modification requires identifying all competing residues before synthesis. Lysine, cysteine, aspartic acid, glutamic acid, serine, threonine, tyrosine, histidine, and terminal groups can influence chemistry depending on the selected activation method. The practical design rule is simple: introduce one intended handle, protect or avoid competing handles where possible, and confirm that the selected conjugation reaction is orthogonal to the rest of the molecule.
A conjugate is useful only if both the peptide and oligonucleotide retain the functions that justified their selection. For peptides, the attachment site should avoid receptor-binding motifs, enzyme recognition residues, epitope residues, cell-penetrating motifs, cleavage sites, and structural constraints such as cyclization positions. For oligonucleotides, the modification should avoid disrupting primer extension, hybridization, antisense recognition, aptamer folding, siRNA guide strand function, or immobilization orientation unless the design intentionally requires that change.
The best attachment site is usually the site that is chemically accessible, synthetically feasible, analytically confirmable, and least likely to interfere with function. In early discovery, it is often useful to compare two orientations, such as N-terminal versus C-terminal peptide attachment or 5' versus 3' oligonucleotide modification, when the functional region is uncertain.
Peptide-side attachment design begins with the sequence. The project team should identify whether the N-terminus, C-terminus, or a side chain can tolerate modification without changing activity. The peptide may also need a spacer between the sequence and the conjugation handle to reduce steric hindrance, improve solubility, or move the oligonucleotide away from a functional motif.
N-terminal modification is one of the most common strategies for peptide-oligonucleotide conjugation because the N-terminus is a defined, accessible position during solid-phase peptide synthesis. It can be functionalized with groups such as amine, azide, alkyne, biotin, maleimide-compatible spacers, or other conjugation handles. N-terminal attachment is often preferred when the peptide's active region is internal or C-terminal, or when the N-terminus is not required for receptor recognition, enzymatic activity, or structural folding.
The main risk is functional interference. Some peptides require a free N-terminal amine for activity, charge state, protease recognition, or binding. In such cases, adding a linker at the N-terminus may reduce performance even if the conjugation chemistry succeeds. Before specifying N-terminal attachment, the project team should check whether the peptide is known to require a free N-terminus or an N-terminal modification such as acetylation.
C-terminal modification is useful when the N-terminus is functionally important or when the desired conjugate orientation requires the peptide to extend from the oligonucleotide in an N-to-C direction. C-terminal handles may be introduced through modified resins, linker strategies, terminal cysteine addition, C-terminal amide designs, or other synthesis routes depending on the peptide structure and required handle.
C-terminal attachment can be attractive for ligands, epitopes, and peptide tags whose N-terminal region must remain exposed. However, the C-terminus may also participate in activity, especially in short bioactive peptides. The specification should state whether the C-terminus must be free acid, amide, extended with a spacer, or modified with a reactive group. Ambiguity between "C-terminal attachment" and "C-terminal amidation plus separate side-chain attachment" can cause avoidable quotation delays.
Cysteine side-chain attachment is widely used for site-specific conjugation because a single engineered cysteine provides a thiol handle that can react with thiol-selective chemistries such as maleimide-based linkers. This approach is useful when neither terminus should be modified or when the peptide needs to be attached through a defined internal position.
The design must clarify whether the cysteine is native, engineered, terminal, internal, protected, or part of a disulfide bond. A peptide containing more than one free cysteine may produce multiple conjugation products unless the synthesis strategy includes selective protection or orthogonal deprotection. If the peptide requires a disulfide bridge for activity, an additional conjugation cysteine must be designed carefully so that it does not scramble disulfide formation or create unwanted oxidation products.
Lysine side-chain attachment uses the ε-amino group of lysine as a modification site. This can be useful when the peptide has a lysine that is distant from the functional motif or when an orthogonally protected lysine is intentionally incorporated as a handle. Lysine-based attachment can support amide bond formation, labeling, biotinylation, spacer installation, and other modifications.
The main concern is selectivity. If the peptide contains multiple lysines and a free N-terminus, amine-reactive chemistry can produce a mixture unless only one amine is available or selectively deprotected. When lysine is selected as the attachment site, the inquiry should specify the exact residue position, such as "modify Lys7 side chain with azide-containing spacer," rather than simply "lysine modification."
A spacer separates the peptide sequence from the conjugation handle or from the oligonucleotide after conjugation. Common spacer concepts include short alkyl spacers, aminohexanoic acid-type spacers, PEG-like hydrophilic spacers, glycine/serine-rich peptide spacers, and other application-specific designs. The spacer is not a decorative feature; it can determine whether the peptide remains accessible after conjugation.
Spacer-containing handles are especially useful when the oligonucleotide is bulky relative to the peptide, when the peptide must bind a protein target, when the conjugate will be immobilized, or when steric hindrance could reduce hybridization or receptor binding. The inquiry should describe spacer preference if known, or state the application so that an appropriate spacer can be recommended.
Oligonucleotide attachment site design determines orientation, hybridization behavior, nuclease exposure, strand recognition, and compatibility with downstream workflows. A peptide attached to the 5' end may behave differently from the same peptide attached to the 3' end or an internal base. For this reason, oligonucleotide-side specifications should always include sequence direction, strand identity, modification position, chemistry handle, backbone type, and any existing labels or terminal modifications.
The 5' end is frequently selected for peptide-oligonucleotide conjugation because it is synthetically accessible and often compatible with terminal modifiers such as amine, thiol, azide, alkyne, biotin, fluorescent dyes, or linker phosphoramidites. A 5' peptide attachment may be suitable for probes, aptamer conjugates, antisense designs, hybridization capture systems, and delivery-oriented constructs where the 5' terminus can tolerate a bulky group.
The risk is application-specific. Some oligonucleotides require a free 5' phosphate, 5' hydroxyl, or defined 5' structure for enzymatic ligation, polymerase extension, cellular recognition, or strand loading. If the oligonucleotide will be used in a biological pathway sensitive to 5' chemistry, this must be stated before selecting 5' attachment.
The 3' end is often chosen when the 5' end must remain available or when the conjugate should be oriented with the peptide at the downstream terminus. 3' modification can also be useful for nuclease protection, immobilization orientation, steric control, and certain probe formats. Depending on the oligonucleotide vendor's capabilities, 3' handles may be introduced through modified solid supports or post-synthetic modification strategies.
The key risk is interference with extension or enzymatic processing. A 3' modification generally prevents polymerase extension from that terminus, which may be desired for a probe but unacceptable for a primer. The inquiry should state whether the oligonucleotide will be used as a primer, probe, antisense strand, guide strand, passenger strand, aptamer, capture strand, or structural component.
Internal oligonucleotide modification places the peptide attachment site within the sequence rather than at either terminus. This can be useful when both termini must remain unmodified, when a peptide must be displayed from a defined internal position, or when the conjugate is designed to create a particular spatial arrangement. Internal modifications may use modified bases, amino modifiers, azide modifiers, alkyne modifiers, or other specialized building blocks.
Internal modification requires more careful design than terminal modification. The selected position may affect duplex stability, aptamer folding, mismatch tolerance, steric accessibility, and synthesis yield. For functional oligonucleotides, internal attachment should avoid conserved binding motifs, catalytic motifs, seed regions, primer-binding regions, and structural stems unless the modification has been experimentally validated.
Many peptide-oligonucleotide conjugates use oligonucleotides that already contain modifications, such as phosphorothioate linkages, 2'-O-methyl RNA, 2'-fluoro RNA, locked nucleic acid-type bases, methylated bases, fluorescent dyes, quenchers, biotin, spacers, or terminal blocking groups. These features may improve stability or function, but they can also affect synthesis, purification, solubility, and conjugation compatibility.
A good inquiry should list every oligonucleotide modification in sequence context. It should also state whether the oligonucleotide has already been synthesized or still needs to be ordered with a compatible handle. If the oligonucleotide is supplied by another vendor, the peptide manufacturer or conjugation partner may need information about salt form, purity, concentration, reducing conditions for thiol handles, and analytical data.
| Attachment Site | Advantage | Risk | Best-Fit Use |
| Peptide N-terminus | Defined position; convenient during peptide synthesis | May disrupt activity if a free N-terminus is required | Peptides with internal or C-terminal functional motifs |
| Peptide C-terminus | Preserves N-terminal recognition when needed | May conflict with required C-terminal acid or amide state | Ligands, epitopes, and tags requiring N-terminal exposure |
| Peptide cysteine side chain | Strong site-specific handle when only one free thiol is present | Multiple cysteines may cause mixed products or oxidation | Internal attachment designs and thiol-maleimide conjugation |
| Peptide lysine side chain | Useful internal amine handle with orthogonal protection | Multiple amines may reduce selectivity | Designs requiring defined side-chain modification |
| Oligo 5' end | Common terminal modification site; clear orientation | May interfere with 5' phosphate-dependent applications | Probes, capture strands, aptamers, and delivery conjugates |
| Oligo 3' end | Useful when 5' end must remain available | Blocks extension from the 3' terminus | Non-extendable probes and orientation-controlled conjugates |
| Oligo internal position | Enables precise spatial display within a sequence | May affect duplex stability, folding, or synthesis yield | Aptamers, structural oligos, and specialized probe formats |
Table 1 Attachment Site Comparison for Peptide-Oligonucleotide Conjugates
After the attachment sites are selected, the next step is matching peptide and oligonucleotide handles to a compatible linker chemistry. The handle pair should be chemically selective, stable under planned reaction conditions, compatible with the peptide and oligonucleotide sequences, and practical to purify. The design should also consider whether the linker is homobifunctional, heterobifunctional, cleavable, non-cleavable, hydrophilic, rigid, flexible, short, or long.
Thiol-maleimide chemistry is a common strategy when the peptide or oligonucleotide contains a single free thiol and the other component carries a maleimide group. For peptide-side design, an engineered cysteine can provide the thiol. For oligonucleotide-side design, thiol-modified or maleimide-compatible oligonucleotides may be used depending on the workflow. The reaction is attractive because it can be selective when competing thiols are absent.
The main design cautions are thiol oxidation, maleimide hydrolysis, and unintended reaction with additional thiols. Thiol-modified oligonucleotides may require reduction and desalting before conjugation. Peptides containing disulfides, free cysteines, reducing agents, or thiol-containing additives require special review. The inquiry should state whether the desired linkage is a stable thioether-type conjugate, a reducible disulfide, or another sulfur-based design.
Azide-alkyne click chemistry is widely used for bioorthogonal conjugation because azides and alkynes are generally absent from unmodified peptides and oligonucleotides. Either component may carry the azide while the other carries an alkyne. A peptide may be synthesized with an azide-containing amino acid, N-terminal azido group, propargyl-type handle, or alkyne-bearing spacer. An oligonucleotide may be ordered with a 5', 3', or internal azide or alkyne modification.
The specification should distinguish copper-catalyzed azide-alkyne cycloaddition from copper-free strain-promoted designs. Copper-catalyzed click chemistry can be efficient but may require careful control of copper, ligand, reducing agent, and purification conditions. Copper-free strain-promoted chemistry avoids copper but may introduce a larger strained alkyne group. The better choice depends on oligonucleotide sensitivity, peptide stability, scale, purification method, and downstream application.
Amine-carboxyl coupling forms an amide bond and is often considered because peptides naturally contain amino and carboxyl groups. However, this chemistry is not automatically site-specific. A peptide may contain an N-terminal amine, lysine side-chain amines, aspartic acid or glutamic acid side-chain carboxyls, and a C-terminal carboxyl group. Without protection or pre-installed activated handles, multiple products can form.
Amide-forming strategies are most useful when the design includes a single available amine or carboxyl group, an orthogonally protected residue, or a pre-functionalized linker. For example, an oligonucleotide with a terminal amine can be coupled to an activated ester-bearing linker, or a peptide with a selectively available carboxyl group can be activated under controlled conditions. The inquiry should clarify which amine or carboxyl is intended to react.
Some peptide-oligonucleotide conjugates require more than one functional element, such as a peptide ligand, oligonucleotide strand, biotin capture tag, fluorescent dye, quencher, spacer, cleavable linker, or affinity handle. Multifunctional designs are useful, but they increase the risk of chemical incompatibility and analytical complexity. Every additional label may affect solubility, purification, mass analysis, absorbance, fluorescence, and biological performance.
For multifunctional designs, the inquiry should define the priority of each feature. For example, a fluorescent label may be required for imaging, a biotin tag for immobilization, and a peptide for cell targeting. If all are needed in the same construct, their positions should be separated logically so that one function does not block another. It is often safer to place capture or detection tags at a terminus or on a spacer rather than directly next to a functional peptide motif.
| Peptide Handle | Oligo Handle | Linker Chemistry | Key Caution |
| Single cysteine thiol | Maleimide-modified oligo | Thiol-maleimide conjugation | Confirm no competing free cysteines or thiol additives |
| Maleimide-bearing peptide | Thiol-modified oligo | Thiol-maleimide conjugation | Reduce and desalt thiol oligo before use if required |
| Azide-modified peptide | Alkyne-modified oligo | Azide-alkyne click chemistry | Choose copper-catalyzed or copper-free conditions deliberately |
| Alkyne-modified peptide | Azide-modified oligo | Azide-alkyne click chemistry | Check peptide and oligo tolerance to reaction additives |
| Single available amine | Activated ester or carboxyl-linked oligo | Amide bond formation | Avoid multiple peptide amines unless protected |
| Biotinylated peptide plus conjugation handle | Reactive terminal oligo handle | Multifunctional conjugate design | Separate capture tag and conjugation site with suitable spacers |
Table 2 Functional Group Matching for Peptide-Oligonucleotide Linker Design
Many peptide-oligonucleotide conjugation problems begin before synthesis, when the inquiry does not define the exact handle, position, orientation, or functional priority. These mistakes can lead to quotation delays, low conjugation yield, heterogeneous products, failed purification, or a conjugate that is chemically correct but biologically unsuitable.
A missing spacer can place the peptide too close to the oligonucleotide, the surface, the dye, or the capture tag. This may block target binding, reduce hybridization, alter folding, or produce unexpected steric effects. Short linkers may be suitable when a compact structure is needed, but they should be selected intentionally rather than by default.
When unsure, the inquiry should describe the application instead of guessing spacer length. For example, a conjugate intended for receptor binding may require more separation than a conjugate used only as a calibration standard. A conjugate intended for immobilized capture may require different spacing than one used in solution.
Multiple reactive groups can turn a site-specific plan into a mixture. A peptide with several lysines is not ideal for nonspecific amine coupling if only one attachment position is desired. A peptide with multiple cysteines is not automatically suitable for thiol-maleimide conjugation unless the cysteines are differentially protected or only one is free. An oligonucleotide with both a terminal amine and an internal reactive modification must be reviewed to confirm which group is intended to react.
The specification should identify all reactive groups and state the desired one. A helpful format is "reactive handle: C-terminal cysteine only; native Lys residues should remain unmodified" or "5' amino modifier is intended for conjugation; 3' dye must remain unchanged."
Competing residues may not be obvious to non-specialists. Lysine, cysteine, aspartic acid, glutamic acid, and terminal groups are common sources of competing reactivity, but other residues may also influence side reactions depending on pH, activation chemistry, oxidation conditions, or purification method. If a peptide contains methionine, tryptophan, multiple cysteines, acid-labile motifs, or aggregation-prone regions, the conjugation plan may need adjustment.
Procurement teams should avoid simplifying the specification to "standard conjugation" when the sequence contains reactive residues. A sequence-level review is usually needed before confirming the final handle and protecting group strategy.
Oligonucleotide orientation errors are common when sequence direction is omitted. A vendor may need to know whether the sequence is written 5' to 3', whether the peptide should be attached to the 5' or 3' end, whether the strand is sense or antisense, and whether internal modifications are counted from the 5' end. Ambiguous orientation can produce a conjugate that has the requested sequence but the wrong functional arrangement.
A complete oligo specification should include sequence direction, backbone chemistry, terminal groups, internal modifications, strand role, purification grade, and existing analytical data if the oligo is supplied by the customer. For duplexes, specify which strand receives the peptide and whether the conjugate should be delivered single-stranded, annealed, desalted, HPLC-purified, or otherwise processed.
A strong inquiry does not need to be perfect, but it should provide enough information for feasibility review. If some details are unknown, state the uncertainty clearly. It is better to send an incomplete specification for technical review than to guess a functional group placement that later requires redesign.
Provide the full peptide sequence from N-terminus to C-terminus. Mark any D-amino acids, non-natural residues, cyclization sites, disulfide bonds, post-translational modifications, terminal acetylation, terminal amidation, labels, or solubility tags. State the desired peptide attachment site, such as N-terminal, C-terminal, Cys side chain, Lys side chain, or a specific inserted handle. If the handle is not fixed, describe which peptide residues or termini must remain unmodified for function.
Provide the oligonucleotide sequence in 5' to 3' orientation and identify whether it is DNA, RNA, modified RNA, antisense oligonucleotide, siRNA strand, aptamer, primer, probe, or another format. List all terminal and internal modifications. State the desired oligo handle, such as 5' amine, 3' thiol, internal azide, 5' alkyne, or another modification. If the oligo will be supplied by another vendor, provide purity, salt form, concentration, and analytical documentation if available.
State whether a specific linker chemistry is required or whether recommendations are acceptable. Useful details include desired linker length, flexibility, hydrophilicity, charge, cleavability, stability, copper-free requirement, PEG-like spacing, alkyl spacing, or compatibility with immobilization. If the linker was selected based on a publication or previous batch, provide the exact structure or description rather than a shorthand name that may be interpreted differently by different vendors.
Define the required purity based on application. Screening assays may tolerate a different purity threshold than in vivo studies, structural studies, quantitative binding assays, or regulated development workflows. Common analytical expectations may include HPLC purity, LC-MS or MALDI-MS identity confirmation, UV quantification for oligonucleotide content, and documentation of final conjugate mass. For complex conjugates, additional characterization may be needed to distinguish unconjugated peptide, unconjugated oligo, hydrolyzed linker, truncated peptide, or partially modified products.
Explain how the conjugate will be used. A delivery conjugate, imaging probe, hybridization probe, aptamer-peptide construct, affinity reagent, immune assay reagent, enzyme substrate, or analytical standard may require different attachment orientation and purity. The application helps determine whether the peptide or oligonucleotide function is more sensitive to modification, whether a spacer is needed, and whether the linker should be stable or cleavable.
Creative Peptides can support custom peptide synthesis projects that require defined terminal modification, side-chain functionalization, spacer installation, labeling, or conjugation-ready handles. For peptide-oligonucleotide conjugation inquiries, the most useful starting point is a clear description of the desired peptide sequence, the intended attachment site, and any functional residues that should not be modified.
In many projects, the customer already has an oligonucleotide design from an oligo supplier but needs a peptide that is compatible with that handle. In other cases, the peptide sequence is fixed, but the best oligonucleotide handle is still uncertain. Creative Peptides can review peptide-side feasibility, suggest practical peptide handles, assess competing residues, and help align terminal or side-chain functionalization with the planned conjugation chemistry.
This review is especially helpful for multifunctional constructs containing spacers, fluorescent labels, biotin, non-natural amino acids, cyclization motifs, cysteine residues, or solubility-sensitive sequences. The goal is not to force every project into a single chemistry platform, but to define a specification that can be synthesized, purified, characterized, and used reliably in the intended workflow.
Peptide-oligonucleotide conjugation succeeds when the chemistry, attachment site, spacer, sequence context, and application are designed together. A linker choice cannot compensate for an incompatible handle placement, and a reactive handle cannot guarantee success if competing residues, oligo orientation, or functional motifs are overlooked.
If your project specification is incomplete, send the available peptide sequence, oligonucleotide sequence, intended application, preferred attachment site, and any known linker requirements for technical review. A preliminary compatibility check can help identify missing spacer needs, competing reactive groups, uncertain oligo orientation, or handle mismatches before synthesis begins. This reduces redesign risk and helps convert a concept into a practical custom peptide-oligonucleotide conjugation request.
The best site depends on which part of the peptide must remain functional. N-terminal attachment is convenient when the N-terminus is not involved in activity. C-terminal attachment is useful when the N-terminus must remain exposed. Side-chain attachment through cysteine or lysine is useful when both termini should remain unchanged, but competing residues must be controlled.
Use 5' modification when the 5' end can tolerate a bulky group and the application does not require a free 5' phosphate or hydroxyl. Use 3' modification when the 5' end must remain available or when a non-extendable probe orientation is desired. Internal modification is possible but requires closer review of hybridization, folding, and sequence function.
Common peptide-side handles include N-terminal amines, azides, alkynes, engineered cysteine thiols, maleimide-compatible handles, lysine side-chain amines, biotin labels, fluorescent labels, and spacer-bearing functional groups. The correct choice depends on the oligo handle and the required conjugation chemistry.
A spacer separates the peptide from the oligonucleotide or label, helping reduce steric hindrance and preserve binding, hybridization, folding, or immobilization performance. Spacer need is especially important for bulky oligonucleotides, receptor-binding peptides, aptamers, capture probes, and multifunctional conjugates.
Provide the peptide sequence, oligonucleotide sequence, desired attachment sites, functional handles, existing modifications, linker preference, purity requirement, analytical expectations, and intended application. Incomplete specifications can still be reviewed if uncertainties are clearly stated.
